A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 70 to 80 sites worldwide.
Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

开始日期2025-01-20

申办/合作机构

AbbVie, Inc.

NCT06093503

/ Withdrawn临床3期

Phase 3, Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Combined With Osimertinib vs Platinum-Based Chemotherapy in Subjects With c-Met Overexpressing (OE) EGFR Mutant, Locally Advanced/Metastatic Non-Squamous NSCLC After a First Progression on Prior Third Generation EGFR TKi Treatment

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how telisotuzumab vedotin in combination with osimertinib affects the disease state compared to standard of care in adult participants with locally advanced/metastatic non-squamous NSCLC that has a mutation in the epidermal growth factor receptor (EGFR) gene and that overexpresses the c-Met protein. Change in disease activity will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC that overexpresses the c-Met protein. Participants are randomly placed in one of the two groups to receive telisotuzumab vedotin and osimertinib or standard of care chemotherapy. Approximately 250 adult participants with locally advanced/metastatic non-squamous NSCLC that has a mutation in the EGFR gene and that overexpresses the c-Met protein will be enrolled in the study in approximately 180 sites worldwide.
Participants will receive intravenous telisotuzumab vedotin every 2 weeks in combination with oral osimertinib tablets daily or standard of care chemotherapy (carboplatin/pemetrexed or cisplatin/pemetrexed as prescribed by the physician). Overall duration of the study is estimated to be approximately 47 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

开始日期2024-05-31

申办/合作机构

AbbVie, Inc.

NCT05513703

/ Terminated临床2期

Phase 2, Open-Label Study in Subjects With Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine how telisotuzumab vedotin affects the disease state in adult participants with previously untreated participants with MET amplified non-squamous NSCLC. Change in disease activity will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of MET amplified non-squamous NSCLC. Participants receive intravenously (IV) infused of telisotuzumab vedotin. Approximately 70 adult participants with previously untreated MET amplified locally advanced/metastatic non-squamous NSCLC will be enrolled in the study in approximately 110 sites worldwide.
Participants will receive IV telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

开始日期2022-11-21

申办/合作机构

AbbVie, Inc.

100 项与 Telisotuzumab vedotin 相关的临床结果

登录后查看更多信息

100 项与 Telisotuzumab vedotin 相关的转化医学

登录后查看更多信息

100 项与 Telisotuzumab vedotin 相关的专利（医药）

登录后查看更多信息

541

项与 Telisotuzumab vedotin 相关的文献（医药）

2025-12-31·mAbs

Antibodies to watch in 2025

Review

作者: Kapoor, Vaishali ; Kaplon, Hélène ; Crescioli, Silvia ; Visweswaraiah, Jyothsna ; Reichert, Janice M. ; Wang, Lin

The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025. In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (®), and antibody-drug conjugate (ADC) sacituzumab tirumotecan (®). We also discuss 30 investigational antibody therapeutics for which marketing applications were undergoing review by at least one regulatory agency, as of our last update on December 9, 2024, including ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab deruxtecan, trastuzumab botidotin, becotatug vedotin, and trastuzumab rezetecan. Of 178 antibody therapeutics we include in the late-stage pipeline, we summarize key data for 18 for which marketing applications may be submitted by the end of 2025, such as bi- or multispecific antibodies denecimig, sonelokimab, erfonrilimab, and anbenitamab. Key trends in the development and approval of antibody formats such as bispecifics and ADCs, as well as clinical-phase transition and global approval success rates for these antibody formats, are reported.

2025-12-31·mAbs

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity

作者: Gesner, Thomas ; Logel, Claude ; Xie, Kathleen T. ; Cebe, Regis ; Wu, Nila C. ; Li, Xun ; Shi, Xingyi ; Velazquez, Roberto ; Simmons, Quincey ; Tschantz, William R. ; Barzaghi-Rinaudo, Patrizia ; Korn, Joshua ; Sagar, Vivek ; Hainzl, Dominik ; Malamas, Anthony ; Mercan, Samuele ; Green, Andrew ; McLaughlin, Margaret ; Huber, Thomas ; Mueller, Kathrin ; Synan, Alyssa ; D’Alessio, Joseph A.

P-cadherin (pCAD) and LI-cadherin (CDH17) are cell-surface proteins belonging to the cadherin superfamily that are both highly expressed in colorectal cancer.This co-expression profile presents a novel and attractive opportunity for a dual targeting approach using an antibody-drug conjugate (ADC).In this study, we used a unique avidity-driven in vitro screening approach to generate pCAD x CDH17 bispecific antibodies that selectively target cells expressing both antigens over cells expressing only pCAD or only CDH17.Based on in vitro binding and inhibition of cell proliferation results, we selected a lead bispecific antibody to link to the cytotoxic payload monomethyl auristatin E (MMAE) to generate a pCAD x CDH17 bispecific MMAE ADC.In in vivo dual flank mouse models, we demonstrated antitumor activity of the bispecific ADC in tumors expressing both antigens but not in tumors expressing only pCAD or only CDH17.Overall, the preclin. data presented here support the proof-of-concept bispecific antibody discovery approach, demonstrating a rational design for screening antibodies by prioritizing cross-arm avid IgGs to target dual-pos. cells.

2025-09-01·DRUGS

Telisotuzumab Vedotin: First Approval

Review

作者: Blair, Hannah A

Telisotuzumab vedotin (telisotuzumab vedotin-tllv; EMRELIS^™), an antibody-drug conjugate (ADC) directed against c-mesenchymal-epithelial transition factor (c-MET) protein, is being developed by AbbVie for the treatment of solid tumours. On 14 May 2025, telisotuzumab vedotin received accelerated approval in the USA for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression, as determined by an FDA-approved test, who have received a prior systemic therapy. This article summarizes the milestones in the development of telisotuzumab vedotin leading to this first approval for NSCLC.

152

项与 Telisotuzumab vedotin 相关的新闻（医药）

2025-10-26

·Biotech前瞻

c-Met ADC Ⅰ期篮式研究：胰腺导管腺癌队列结果惊艳

点击蓝字关注我们本期看点胰腺导管腺癌（PDAC）预后极差，是全球癌症死亡主因之一，5年生存率仅5–13%。目前全身治疗以化疗为主（如FOLFIRINOX或白蛋白紫杉醇+吉西他滨方案），仅能略延长生存。针对常见基因突变的靶向药效果有限。 2025 ESMO上公布了艾伯维的 c-Met ADC telisotuzumab adizutecan（ABBV-400，商品名 Temab-A）在既往接受治疗的局部晚期或转移性胰腺导管腺癌（PDAC）患者中表现出可观的抗肿瘤活性和可管理的安全性。其安全性特征与该药在其他肿瘤类型中的表现一致。本期内容 01 c-Met ADC丨Temab-A 02 2025 ESMO 丨Temab-A 胰腺癌疗效数据 03 安全性及生物标志物分析 04 总结与展望【01 c-Met ADC丨telisotuzumab adizutecan】 Temab-A（研发代号ABBV-400，通用名 Telisotuzumab Adizutecan）是艾伯维（AbbVie）公司开发的一款靶向c-Met蛋白的抗体偶联药物（ADC）。它由靶向c-Met蛋白的单克隆抗体、可切割的连接子和一种强效的拓扑异构酶1抑制剂（TOP1i）载荷药物“adizutecan”组成。 Temab-A 作用机制早期研究显示，Temab-A不仅对c-Met高表达的肿瘤有效，对c-Met低至中度表达的肿瘤也显示出活性，可能让更广泛的患者受益。 telisotuzumab vedotin（Teliso-V）作用机制 Temab-A与艾伯维另一款已经上市的c-Met ADC药物Teliso-V的关键区别在于所携带的细胞毒载荷不同：Teliso-V使用微管抑制剂MMAE，而Temab-A使用的是拓扑异构酶1抑制剂。这可能导致两者的疗效、安全性和适用人群有所不同。 02 2025 ESMO 丨Temab-A 胰腺癌疗效数据研究设计本报告来自一项 I 期篮式研究（NCT06084481），研究对象为 18 岁及以上、多种晚期实体瘤的患者，按肿瘤类型分为 9 个队列。本文评述的是 PDAC 队列的研究设计要点与患者特征。试验设计示意图入组标准：组织学或细胞学确诊为胰腺导管腺癌；无生物标志物预先筛选；在一线治疗期间或治疗后出现进展；ECOG 体能状态 0–1；若术后/辅助或新辅助化疗后 6 个月内复发亦允许入组。给药方案：研究药为针对 c-Met 的抗体偶联药物 telisotuzumab adizutecan（ABBV-400，Temab-A），按三周一次给药，剂量为 3.0 mg/kg 或 2.4 mg/kg。经安全监测委员会决策，剂量由 3.0 mg/kg 下调至 2.4 mg/kg；分别有 13 例与 29 例患者于治疗开始时接受两种剂量。主要与次要终点：主要终点为研究者依据 RECIST v1.1 评估的确证客观缓解率（cORR）；次要终点包括缓解持续时间（DOR）、临床获益率（CBR）、无进展生存期（PFS）、总生存期（OS）及安全性评估。患者基线特征：本队列共纳入 42 例转线治疗患者，中位年龄 69 岁（45–86），男性 57%，白人 86%；ECOG 大多为 1（57%），基线有转移者占 88%。既往一线治疗中 62% 接受 FOLFIRINOX，部分患者（29%）既往有放疗。患者既往系统治疗线数中位为 1（范围 1–3），从确诊到入组的中位时间 1.2 年（0.3–6.3）。试验主要结果疗效在 42 例二线 PDAC 患者中：确证客观缓解率（cORR）：23.8%；确证临床获益率（cCBR）：81.0%；中位缓解持续时间（DOR）：6.9 个月；中位无进展生存期（PFS）：5.4 个月（研究期间 73.8% 患者发生进展）；中位总生存期（OS）：7.9 个月（数据截止时 54.8% 患者已死亡）。按既往一线方案分层的结果：既往接受 FOLFIRINOX（n = 26）：cORR 15.4%，cCBR 80.8%；中位 PFS 5.0 个月，中位 OS 7.1 个月（数据截止时 73.1% 进展，57.7% 死亡）。既往接受吉西他滨 + nab-紫杉醇：cORR 40.0%，cCBR 80.0%；中位 PFS 6.3 个月，中位 OS 11.6 个月（数据截止时 80.0% 进展，53.3% 死亡）。【03 安全性及生物标志物分析】安全性中位治疗持续时间为 4.3 个月（0.7–14.3），中位相对剂量强度为 90%（64%–100%）。任何级别 TEAE 发生率 100%；≥3 级 TEAE 发生率 81%；严重 TEAE 发生率 52%。与治疗相关不良事件（TRAEs）：任何级别 93%，≥3 级 57%，严重 TRAE 19%。常见血液学不良事件（任何级别 / ≥3级）：贫血 50% / 38%；中性粒细胞减少 43% / 24%；白细胞减少 19% / 7%；淋巴细胞减少 12% / 7%；血小板减少 12% / 5%。常见非血液学不良事件（任何级别 / ≥3级）：恶心 55% / 0%；食欲下降 48% / 2%；疲劳 41% / 2%；呕吐 36% / 0%；外周水肿 26% / 2%。因 TRAE 导致剂量下调、剂量中断、或停止治疗的比例分别为 48%、38% 与 14%。经审定的间质性肺病/肺炎发生率为 4.8%，其中出现了单例的 2 级与 3 级事件。生物标志物免疫组化分析显示，所有可检测的肿瘤样本均存在 c-Met 蛋白染色（2+ 或 3+ 强度）。诊断样本与近期取样之间的 c-Met 表达率一致。研究者指出需进一步评估 c-Met 表达与治疗反应之间的相关性。 04 总结与展望 Temab-A（telisotuzumab adizutecan）在既往接受过一线治疗的局部晚期/转移性 PDAC 患者中显示出可观的抗肿瘤活性（二线总体 cORR 23.8%、cCBR 81.0%，DOR 中位 6.9 个月），且安全性总体可管理，但存在较高比例的 ≥3 级不良事件和剂量调整需求。不同既往一线方案的亚组（如 FOLFIRINOX vs. 吉西他滨 + nab-紫杉醇）显示出疗效差异，提示既往治疗背景可能影响后线反应。免疫组化发现普遍存在的 c-Met 表达支持该靶点在 PDAC 中的治疗价值，但 c-Met 表达与疗效的关联仍需在更大规模、前瞻性的研究中进一步验证。建议在后续更大样本的前瞻性试验中继续评估 Temab-A 的疗效与安全性，并探索基于 c-Met 或其他生物标志物的患者分层策略以优化获益-风险比。 ★

抗体药物偶联物临床结果临床1期

2025-10-13

·PRNewswire

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-treat cancers. NORTH CHICAGO, Ill., Oct. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will unveil new data from its robust antibody-drug conjugate (ADC) platform at the 2025 European Society for Medical Oncology (ESMO) Congress, taking place October 17-21, in Berlin, Germany. Data from investigational and approved ADCs across AbbVie's portfolio such as telisotuzumab adizutecan (Temab-A),1-3 ABBV-706,4,5 and Emrelis™ (telisotuzumab vedotin),6 in patients with difficult-to-treat tumor types where there is urgent need for additional treatment options,7-15 will be featured in multiple presentations. "Despite recent progress in the treatment of advanced solid tumors, patients still face limited options and pressing unmet needs," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "The compelling data we are sharing at ESMO showcases how we are advancing targeted therapies across a range of solid tumors and highlights the potential of our portfolio." Key highlights AbbVie will present three oral presentations for Temab-A, a next-generation, investigational c-Met directed ADC with a novel topoisomerase 1 inhibitor (Top1i) payload. Phase 1 results with Temab-A both as a monotherapy and in combination across advanced, solid tumors will be presented: Combination with bevacizumab (Bev) in Colorectal Cancer (CRC): In biomarker unselected patients with advanced CRC who have received three or more prior lines of therapy (NCT05029882), treatment with 2.4 mg/kg dose of Temab-A plus Bev (n=30) achieved an objective response rate (ORR) of 26.7% compared to an ORR of 0% with trifluridine/tipiracil with Bev (the current standard of care (SOC), n = 20).1 Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 67% and 65% of patients, respectively.1 Monotherapy in MET-Amplified Solid Tumors: Among 100 patients with advanced MET-amplified solid tumors, including non-small cell lung cancer (NSCLC) (n=29), CRC (n=22), gastroesophageal adenocarcinoma (GEA) (n=14), and 16 other tumor types (n=35) who had progressed after SOC treatment (NCT05029882), Temab-A monotherapy achieved an ORR of 46% across all dose levels and tumor types with higher responses observed in patients with NSCLC (69%) and GEA (71%).2 The most common grade ≥3 TEAEs were anemia (40%) and neutropenia (34%).2 Monotherapy in Pancreatic Ductal Adenocarcinoma (PDAC ): Among 42 biomarker unselected patients with advanced/metastatic PDAC who experienced disease progression while receiving or after completing their first-line (1L) therapy (NCT06084481), Temab-A demonstrated an ORR of 24% overall and 40% in patients who received first-line gemcitabine-nab-paclitaxel treatment.3 Grade ≥3 TEAEs occurring in ≥10% of all patients were anemia (38%) and neutropenia (21%).3 "Temab-A continues to show meaningful clinical activity across an expanding range of solid tumors and patient populations, including patients with MET-amplification and increased c-Met expression as we have seen in previously presented data," said Vivek Subbiah, M.D., Chief, Early-Phase Drug Development, Sarah Cannon Research Institute and Temab-A investigator. "These data reinforce Temab-A's potential in multiple solid tumors and thereby warrant its further clinical investigation." AbbVie will also present new analysis from a Phase 1 study of ABBV-706, a SEZ6-directed ADC with a Top1i payload, in relapsed/refractory small cell lung cancer (R/R SCLC) (NCT05599984). A post hoc analysis on data from R/R SCLC patients enrolled in the study, whose tumors had progressed after two lines of therapy (n=80), was done to compare the anti-cancer effect of ABBV-706 monotherapy vs. platinum-based SOC. All patients in this group had received the platinum-based SOC treatment as first-line therapy (1L SOC). Progression-free survival (PFS) during 1L SOC and PFS with ABBV-706 monotherapy as a subsequent line of treatment were analyzed in the same patients by paired Kaplan-Meier analysis. The findings suggest that ABBV-706 may have the potential to replace the platinum-based SOC as a first-line treatment in SCLC.4 In the same trial, ABBV-706 treatment also resulted in rapid clearance of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Patients with 100% ctDNA clearance had significantly higher PFS and overall survival (OS) vs. patients without ctDNA clearance.5 These data highlight the potential of ctDNA as an early response marker in SCLC.5 A Phase 2 study assessing ABBV-706 in combination with atezolizumab as replacement of platinum-based chemotherapy is currently ongoing (NCT07155174) in 1L SCLC. Details on key presentations at the ESMO 2025 Congress are available below and the full abstracts are available via the ESMO online program. Telisotuzumab adizutecan (Temab-A) and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies. Elahere™ (mirvetuximab soravtansine) and Emrelis™ (telisotuzumab vedotin) are approved medicines being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses. Additional information on AbbVie clinical trials is available at . U.S. Prescribing Information for AbbVie Medicines Please see full Prescribing information for ELAHERE™ (mirvetuximab soravtansine-gynx) Please see full Prescribing Information for EMRELIS™ (telisotuzumab vedotin-tllv) About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter) and YouTube. About AbbVie in Oncology AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit . Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. References: Cecchini M, Cruz-Correa M, Han SW, et al. Telisotuzumab Adizutecan (ABBV-400; Temab-A) in Combination With Bevacizumab (Bev) in Patients (Pts) With 3+ Colorectal Cancer (CRC): Dose Expansion Results of a Phase 1 Study. Abstract 731MO presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany. Murciano-Goroff YR, Kuboki Y, Strickler J, et al. Telisotuzumab Adizutecan (ABBV-400; Temab-A) in Patients With MET-Amplified Advanced Solid Tumors: Results From a Phase 1 Study. Abstract 918O presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany. Harding JJ, Strickler J, Henry J, et al. Phase 1 Basket Study of Telisotuzumab Adizutecan (Temab-A), a c-Met Protein-Targeting Antibody-Drug Conjugate (ADC): Results from Patients (Pts) With Pancreatic Ductal Adenocarcinoma (PDAC). Abstract 2214MO presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany. Bar J, Dowlati A, Byers LA, et al. Efficacy of ABBV-706 as second-line treatment for patients with platinum-refractory/resistant small cell lung cancer. Abstract 2777P presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany. Wang S, Wang L, Luo A, et al. ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with relapsed/refractory (R/R) small cell lung cancer (SCLC): Circulating biomarker and molecular response analyses. Abstract 2778P presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany. Mansfield AS, Goldman J, Lee SH, et al. Treatment outcomes in patients (pts) with advanced c-Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modifications in the LUMINOSITY trial. Abstract 1948P presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany. Cassim S, Chepulis L, Keenan R. et al. Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review. BMC Cancer. 2019; 19, 25. doi:10.1186/s12885-018-5169-9 Shalata W, Naamneh R, Najjar W, et al. Current and Emerging Therapeutic Strategies for Limited- and Extensive-Stage Small-Cell Lung Cancer. Med Sci. 2025; 13(3):142. doi:10.3390/medsci13030142 Daamen LA, Molenaar IQ, and Groot VP. Recent Advances and Future Challenges in Pancreatic Cancer Care: Early Detection, Liquid Biopsies, Precision Medicine and Artificial Intelligence. J Clin Med. 2023; 12(23):7485. doi:10.3390/jcm12237485 Cereda V and D'Andrea MR. Pancreatic cancer: failures and hopes—a review of new promising treatment approaches. Explor Target Antitumor Ther. 2025;6:1002299. doi: 10.37349/etat.2025.1002299 Deboever N, Jones CM, Yamashita K, et al. Advances in diagnosis and management of cancer of the esophagus. BMJ. 2024; 385 :e074962 doi:10.1136/bmj-2023-074962 Huang J. Overcoming Therapeutic Barriers in Esophageal Cancer Management. J Cancer Clin Trials. 2025;10,289. doi:10.37421/2577-0535.2025.9.289. Nishimuni M, Claro LCL, and Braghiroli MFM. Advancements and challenges in gastric cancer: epidemiology, biomarkers, and therapeutic strategies. Surg Exp Pathol. 2024;7,19. doi.10.1186/s42047-024-00162-4 Li H, Shen M and Wang S. Current therapies and progress in the treatment of advanced gastric cancer. Front Oncol. 2024; 4:1327055. doi:10.3389/fonc.2024.1327055 Pathak PS, Chan G, Deming DA, et al.State-of-the-art management of colorectal cancer: Treatment advances and innovation. Am Soc Clin Oncol Educ Book, 2024; 44(3), p.e438466. doi:10.1200/EDBK_438466 SOURCE AbbVie WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果临床1期抗体药物偶联物临床2期ASCO会议

2025-10-13

·news.abbvie.com

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

Oncology R&D News New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-treat cancers. NORTH CHICAGO, Ill., Oct. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will unveil new data from its robust antibody-drug conjugate (ADC) platform at the 2025 European Society for Medical Oncology (ESMO) Congress, taking place October 17-21, in Berlin, Germany. Data from investigational and approved ADCs across AbbVie's portfolio such as telisotuzumab adizutecan (Temab-A),1-3 ABBV-706,4,5 and Emrelis™ (telisotuzumab vedotin),6 in patients with difficult-to-treat tumor types where there is urgent need for additional treatment options,7-15 will be featured in multiple presentations. "Despite recent progress in the treatment of advanced solid tumors, patients still face limited options and pressing unmet needs," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "The compelling data we are sharing at ESMO showcases how we are advancing targeted therapies across a range of solid tumors and highlights the potential of our portfolio." Key highlights AbbVie will present three oral presentations for Temab-A, a next-generation, investigational c-Met directed ADC with a novel topoisomerase 1 inhibitor (Top1i) payload. Phase 1 results with Temab-A both as a monotherapy and in combination across advanced, solid tumors will be presented: Combination with bevacizumab (Bev) in Colorectal Cancer (CRC): In biomarker unselected patients with advanced CRC who have received three or more prior lines of therapy (NCT05029882), treatment with 2.4 mg/kg dose of Temab-A plus Bev (n=30) achieved an objective response rate (ORR) of 26.7% compared to an ORR of 0% with trifluridine/tipiracil with Bev (the current standard of care (SOC), n = 20).1 Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 67% and 65% of patients, respectively.1 Monotherapy in MET-Amplified Solid Tumors: Among 100 patients with advanced MET-amplified solid tumors, including non-small cell lung cancer (NSCLC) (n=29), CRC (n=22), gastroesophageal adenocarcinoma (GEA) (n=14), and 16 other tumor types (n=35) who had progressed after SOC treatment (NCT05029882), Temab-A monotherapy achieved an ORR of 46% across all dose levels and tumor types with higher responses observed in patients with NSCLC (69%) and GEA (71%).2 The most common grade ≥3 TEAEs were anemia (40%) and neutropenia (34%).2 Monotherapy in Pancreatic Ductal Adenocarcinoma (PDAC): Among 42 biomarker unselected patients with advanced/metastatic PDAC who experienced disease progression while receiving or after completing their first-line (1L) therapy (NCT06084481), Temab-A demonstrated an ORR of 24% overall and 40% in patients who received first-line gemcitabine-nab-paclitaxel treatment.3 Grade ≥3 TEAEs occurring in ≥10% of all patients were anemia (38%) and neutropenia (21%).3 "Temab-A continues to show meaningful clinical activity across an expanding range of solid tumors and patient populations, including patients with MET-amplification and increased c-Met expression as we have seen in previously presented data," said Vivek Subbiah, M.D., Chief, Early-Phase Drug Development, Sarah Cannon Research Institute and Temab-A investigator. "These data reinforce Temab-A's potential in multiple solid tumors and thereby warrant its further clinical investigation." AbbVie will also present new analysis from a Phase 1 study of ABBV-706, a SEZ6-directed ADC with a Top1i payload, in relapsed/refractory small cell lung cancer (R/R SCLC) (NCT05599984). A post hoc analysis on data from R/R SCLC patients enrolled in the study, whose tumors had progressed after two lines of therapy (n=80), was done to compare the anti-cancer effect of ABBV-706 monotherapy vs. platinum-based SOC. All patients in this group had received the platinum-based SOC treatment as first-line therapy (1L SOC). Progression-free survival (PFS) during 1L SOC and PFS with ABBV-706 monotherapy as a subsequent line of treatment were analyzed in the same patients by paired Kaplan-Meier analysis. The findings suggest that ABBV-706 may have the potential to replace the platinum-based SOC as a first-line treatment in SCLC.4 In the same trial, ABBV-706 treatment also resulted in rapid clearance of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Patients with 100% ctDNA clearance had significantly higher PFS and overall survival (OS) vs. patients without ctDNA clearance.5 These data highlight the potential of ctDNA as an early response marker in SCLC.5 A Phase 2 study assessing ABBV-706 in combination with atezolizumab as replacement of platinum-based chemotherapy is currently ongoing (NCT07155174) in 1L SCLC. Details on key presentations at the ESMO 2025 Congress are available below and the full abstracts are available via the ESMO online program. Title Date/Time Session Abstract / Presentation Number Telisotuzumab Adizutecan (ABBV-400; Temab-A) in Patients With MET-Amplified Advanced Solid Tumors: Results From a Phase 1 Study Sunday, October 19 2:45 - 4:15 PM CEST Oral presentation Proffered paper session: Developmental therapeutics Room: Bremen Auditorium - Hall 6.2 918O Telisotuzumab Adizutecan (ABBV-400; Temab-A) in Combination With Bevacizumab (Bev) in Patients (Pts) With 3+ Colorectal Cancer (CRC): Dose Expansion Results of a Phase 1 Study Sunday, October 19 2:45 - 4:15 PM CEST Mini oral session 1: GI tumors,lower digestive Room: Cologne Auditorium - CityCube A 731MO Phase 1 Basket Study of Telisotuzumab Adizutecan (Temab-A), a c-Met Protein-Targeting Antibody-Drug Conjugate (ADC): Results from Patients (Pts) With Pancreatic Ductal Adenocarcinoma (PDAC) Monday, October 20 8:30 – 10:00 AM CEST Mini oral session 2: GI tumours, upper digestive Room: Bonn Auditorium - Hall 7.1c 2214MO Second progression-free survival (PFS2) and subsequent treatment in patients (pts) with folate receptor alpha (FR⍺)-positive platinum-resistant ovarian cancer (PROC) treated with mirvetuximab soravtansine (MIRV) vs. investigator's choice chemotherapy (ICC): Phase 3 MIRASOL trial Saturday, October 18 12:00 – 12:45 PM CEST Poster 1068P Efficacy of ABBV-706 as second-line treatment for patients with platinum-refractory/resistant small cell lung cancer Saturday, October 18 12:00 – 12:45 PM CEST Poster 2777P Real World Characteristics and Outcomes of Patients with Third Line or Later Metastatic Colorectal Cancer: Magnetic-101 Study Results Sunday, October 19 12:00 – 12:45 PM CEST E-Poster 873eP ABBV-706, a Seizure-Related Homolog Protein 6 (SEZ6)-Targeting Antibody-Drug Conjugate (ADC), in Patients (Pts) With Relapsed/Refractory (R/R) Small Cell Lung Cancer (SCLC): Circulating Biomarker and Molecular Response Analyses Saturday, October 18 12:00 – 12:45 PM CEST Poster 2778P Seizure Related 6 Homolog (SEZ6) Expression Pattern and Prognostic Impact in a Real-World Cohort of Patients With Small Cell Lung Cancer Saturday, October 18 12:00 – 12:45 PM CEST E-Poster 2796eP Companion diagnostic assay for c-Met protein overexpression (OE) to identify patients (pts) who may benefit from telisotuzumab vedotin (Teliso-V) Saturday, October 18 12:00 – 12:45 PM CEST Poster 1951P Treatment outcomes in patients (pts) with advanced c- Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modifications in the LUMINOSITY trial Saturday, October 18 12:00 – 12:45 PM CEST Poster 1948P Ocular surface disorders in patients with c-Met protein- overexpressing NSCLC treated with telisotuzumab vedotin in the LUMINOSITY study Saturday, October 18 12:00 – 12:45 PM CEST Poster 1950P METRIX: International Real-World Study of c-Met Protein Overexpression in Patients With Advanced /Metastatic NSCLC Saturday, October 18 12:00 – 12:45 PM CEST Poster 1923P Telisotuzumab adizutecan (Temab-A) and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies. Elahere™ (mirvetuximab soravtansine) and Emrelis™ (telisotuzumab vedotin) are approved medicines being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses. Additional information on AbbVie clinical trials is available at https://www.clinicaltrials.gov/. U.S. Prescribing Information for AbbVie Medicines Please see full Prescribing information for ELAHERE™ (mirvetuximab soravtansine-gynx) Please see full Prescribing Information for EMRELIS™ (telisotuzumab vedotin-tllv) About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube. About AbbVie in Oncology AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. References: Contacts: Media: Investors: Sourojit (Jit) Bhowmick, Ph.D. Liz Shea jit.bhowmick@abbvie.com liz.shea@abbvie.com Mabel Martinez mabel.martinez@abbvie.com SOURCE AbbVie

临床1期临床结果抗体药物偶联物临床2期

100 项与 Telisotuzumab vedotin 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11344	-	-	DB15104

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
c-Met 阳性的非鳞状非小细胞肺癌	美国	AbbVie, Inc.	2025-05-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期非鳞状非小细胞肺癌	临床3期	-	AbbVie, Inc.	2024-05-31
非鳞状非小细胞肺癌	临床3期	日本	AbbVie, Inc.	2022-01-02
非鳞状非小细胞肺癌	临床3期	阿根廷	AbbVie, Inc.	2022-01-02
非鳞状非小细胞肺癌	临床3期	澳大利亚	AbbVie, Inc.	2022-01-02
非鳞状非小细胞肺癌	临床3期	奥地利	AbbVie, Inc.	2022-01-02
非鳞状非小细胞肺癌	临床3期	比利时	AbbVie, Inc.	2022-01-02
非鳞状非小细胞肺癌	临床3期	巴西	AbbVie, Inc.	2022-01-02
非鳞状非小细胞肺癌	临床3期	保加利亚	AbbVie, Inc.	2022-01-02
非鳞状非小细胞肺癌	临床3期	加拿大	AbbVie, Inc.	2022-01-02
非鳞状非小细胞肺癌	临床3期	智利	AbbVie, Inc.	2022-01-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05513703 (CTgov)	临床2期	转移性非鳞状非小细胞肺癌 \| c-Met 阳性的非鳞状非小细胞肺癌	9	Telisotuzumab Vedotin	衊餘艱襯網艱膚鏇鏇獵 = 齋鹹膚築網願積選夢製繭衊艱壓鹹窪觸艱積願 (鹹選壓簾鹽壓觸鏇製觸, 繭鬱憲築憲齋繭構遞願 ~ 糧範齋餘窪遞窪夢糧淵) 更多	-	2025-10-24
NCT03539536 (LUMINOSITY, WCLC2025)	临床2期	鳞状细胞肺癌三线 \| 二线 MET overexpression	168	Telisotuzumab Vedotin 1.9 mg/kg (c-Met OE Total；No PN ≥3)	衊範製繭衊鹽範鹹願夢(憲夢構構齋願夢顧憲蓋) = 夢網衊淵願鑰鬱艱齋構膚製膚餘觸鬱觸憲壓構 (餘網艱窪憲鬱鹽膚願廠 ) 更多	积极	2025-09-08
				Telisotuzumab Vedotin 1.9 mg/kg (c-Met OE Total；PN ≥3)	衊範製繭衊鹽範鹹願夢(憲夢構構齋願夢顧憲蓋) = 蓋製築餘廠廠繭憲廠憲膚製膚餘觸鬱觸憲壓構 (餘網艱窪憲鬱鹽膚願廠 ) 更多
NCT03539536 (LUMINOSITY, ASCO2025)	临床2期	c-Met阳性非小细胞肺癌二线 c-Met overexpression \| KRAS \| BRAF ... 更多	83	Teliso-V 1.9 mg/kg	餘鹹齋窪鑰憲範獵鑰選(鑰觸簾鬱製獵範憲網鬱) = 簾顧積網鏇顧簾遞蓋積網範餘網選顧齋醖醖淵 (獵襯鑰網網觸夢遞廠窪 ) 更多	积极	2025-05-30
				Placebo	膚膚鏇鹹餘鏇鬱鹽網齋(窪餘窪築襯艱鹹窪齋膚) = 壓鬱壓餘觸積構顧築艱繭壓選艱艱選鑰鑰鹽廠 (繭淵鹽膚觸願觸艱遞鹹 ) 更多
NCT03539536 (LUMINOSITY, FDA_CDER) 人工标引	临床2期	c-Met阳性非小细胞肺癌 MET Overexpression	84	EMRELIS (high c-Met protein overexpression)	鑰壓願網憲齋襯窪積獵(範淵膚鹽壓艱鏇觸構餘) = 遞膚遞鬱蓋鏇顧觸築選積餘築觸選窪鹹蓋餘選 (糧鹹構鏇鹽製壓糧鏇鏇, 24 ~ 46) 更多	积极	2025-05-14
NCT03539536 (LUMINOSITY, ESMO_ELCC2025) 人工标引	临床2期	c-Met阳性非小细胞肺癌 \| 晚期非小细胞肺癌 EGFR Gene Mutation Negative \| MET Overexpression	172	Telisotuzumab vedotin 1.9 mg/kg (c-Met high: ≥50% 3+)	觸憲遞積壓鬱淵餘願醖(願獵夢膚觸鹹壓糧製鹽) = 顧觸積齋簾鏇願觸選獵顧網淵積遞積鬱淵簾襯 (築壓構鹹遞範鬱鏇鬱艱, 24.5 ~ 45.7) 更多	积极	2025-03-26
				Telisotuzumab vedotin 1.9 mg/kg (c-Met intermediate [int]: 25 to <50% 3+)	觸憲遞積壓鬱淵餘願醖(願獵夢膚觸鹹壓糧製鹽) = 鬱蓋製鑰窪鑰艱齋繭糧顧網淵積遞積鬱淵簾襯 (築壓構鹹遞範鬱鏇鬱艱, 15.2 ~ 34.3) 更多
NCT02099058 (Pubmed \| Ann Oncol) 人工标引	临床1期	非小细胞肺癌二线 EGFR Mutation \| MET Overexpression	38	Telisotuzumab vedotin + osimertinib	網鏇襯顧齋觸膚觸網壓(餘憲構構夢觸淵淵顧齋) = peripheral sensory neuropathy (50%), peripheral edema (32%), and nausea (24%) 顧糧願積願製醖廠夢遞 (壓壓製淵構襯廠積鏇壓 ) 更多	积极	2025-01-01
NCT03539536 (ESMO2024)	临床2期	c-Met 阳性的非鳞状非小细胞肺癌	-	Telisotuzumab vedotin	淵蓋壓憲廠構淵齋艱淵(糧鬱餘獵繭膚鏇壓積廠) = 鑰壓齋積蓋窪簾鏇醖鑰夢顧鑰淵鬱衊齋範膚壓 (鑰鬱鏇艱夢襯願夢鹽鹹 )	-	2024-09-14
				Placebo	淵蓋壓憲廠構淵齋艱淵(糧鬱餘獵繭膚鏇壓積廠) = 積鏇窪顧餘簾鹽壓鏇鑰夢顧鑰淵鬱衊齋範膚壓 (鑰鬱鏇艱夢襯願夢鹽鹹 )
NCT02099058 (WCLC2024) 人工标引	临床1期	c-Met阳性非小细胞肺癌 MET Overexpression	30	Teliso-v (c-Met-positive tumor cells with 3+ intensity)	壓艱簾繭憲製衊艱繭製(選淵範顧淵鬱蓋選醖夢) = 衊膚衊醖廠繭艱齋簾顧夢構膚鹽鏇夢夢觸齋窪 (遞齋憲選壓憲顧鹽觸膚 )	积极	2024-09-09
				Teliso-v (below (A cutoff value of 25% c-Met-positive tumor cells with 3+ intensity))	壓艱簾繭憲製衊艱繭製(選淵範顧淵鬱蓋選醖夢) = 鏇選餘鹽範醖網製憲遞夢構膚鹽鏇夢夢觸齋窪 (遞齋憲選壓憲顧鹽觸膚 )
NCT03539536 (LUMINOSITY, Pubmed) 人工标引	临床2期	c-Met阳性非小细胞肺癌 c-Met protein-overexpressing	172	Telisotuzumab vedotin (Teliso-V)	廠遞餘願簾願鬱遞憲遞(壓夢淵鑰製襯範顧繭構) = 衊鹹廠壓築窪膚鏇構鬱衊壓範鬱築網鑰獵鹽廠 (蓋夢鬱艱窪構願繭鹽餘, 21.7 ~ 36.2) 更多	积极	2024-06-06
				Telisotuzumab vedotin (c-Met high)	廠遞餘願簾願鬱遞憲遞(壓夢淵鑰製襯範顧繭構) = 鹹構鏇襯鑰製簾築蓋艱衊壓範鬱築網鑰獵鹽廠 (蓋夢鬱艱窪構願繭鹽餘, 24.2 ~ 46.2) 更多
NCT03539536 (LUMINOSITY, ASCO2024) 人工标引	临床2期	非小细胞肺癌 \| c-Met 阳性的非鳞状非小细胞肺癌三线 c-Met protein overexpression	172	Telisotuzumab vedotin (c-Met High)	遞廠齋憲窪襯艱積網鹹(顧獵廠顧鏇積獵鬱製廠) = 簾膚鑰齋艱繭醖齋膚廠夢憲觸淵艱夢艱顧遞鑰 (齋築範鹽簾糧壓夢醖窪, 24.2 ~ 46.2) 更多	积极	2024-05-24
				Telisotuzumab vedotin (c-Met Int)	遞廠齋憲窪襯艱積網鹹(顧獵廠顧鏇積獵鬱製廠) = 製構構醖齋蓋齋繭觸願夢憲觸淵艱夢艱顧遞鑰 (齋築範鹽簾糧壓夢醖窪, 14.4 ~ 33.4) 更多